Goldman Sachs starts Essity at “neutral,” sees limited near-term catalysts

Goldman Sachs has initiated "Neutral" coverage on Essity (ST:ESSITYb), citing a trough valuation and 14% upside potential driven by the company's strategic shift towards higher-margin segments, which is expected to support long-term sales growth and margin expansion. However, the firm highlights significant margin volatility from pulp and energy costs, a key risk, and notes a lack of immediate catalysts for a re-rating, despite Essity currently trading at a 25% discount to its historical average valuation.

Analysis

Goldman Sachs has initiated coverage on Essity with a "Neutral" rating, presenting a balanced outlook for the hygiene and health company. The firm identifies a compelling valuation, with Essity's shares trading at a 25% discount to their average since 2018 on a 12x CY26 P/E multiple, which Goldman Sachs terms a "trough valuation." The analysis projects 14% upside potential, primarily driven by the company's strategic pivot away from its core tissue business and toward higher-margin segments. This strategic shift is anticipated to support long-term sales growth of approximately 3% and could be enhanced by margin expansion and accretive M&A. However, this potential is tempered by significant risks, most notably margin volatility. Pulp and energy costs, which constitute around 20% of Essity's cost of goods sold, are cited as having historically driven 90% of the company's profitability swings. While recent deflation in these input costs may offer short-term relief, the note cautions that a lack of immediate catalysts could prevent a re-rating of the stock.

Key Decisions for Investors

• Investors should weigh the attractive trough valuation against the noted absence of immediate catalysts, suggesting a potential holding pattern until a clear trigger for a re-rating emerges.
• Closely monitor pulp and energy commodity price movements, as these are the primary drivers of margin volatility and represent the key risk to Essity's profitability.
• For a long-term position, track management's execution on its strategic shift to higher-margin businesses, as this is the fundamental driver for the projected 3% sales growth and margin improvement.
• Given the balanced risk-reward profile outlined in the 'Neutral' rating, consider holding existing positions while awaiting more concrete evidence of margin stabilization or successful strategic execution before adding exposure.